AFFY:OTC-Affymax Inc. (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.01

Change

0.00 (0.00)%

Market Cap

USD 2.61M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

AFFY Stock Forecast & Price:
Based on the Affymax Inc. stock forecasts from 0 analysts, the average analyst target price for Affymax Inc. is not available over the next 12 months. Affymax Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Affymax Inc. is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Affymax Inc.’s stock price was USD 0.01. Affymax Inc.’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +19.23% over the last year.

No recent analyst target price found for Affymax Inc.
No recent average analyst rating found for Affymax Inc.

About Affymax Inc. (AFFY:OTC)

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Company Website : https://www.affymax.com

Address : 630 Fifth Avenue, New York, NY, United States, 10020

Employees : 2

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 5.48

52 Week High : 0.02

Short Ratio : 2.35

52 Week Low : 0.00

Shorted Shares : 18,481,851

200 Day Moving Average : 0.01

Shorted Shares Previous Month : 15,826,827

50 Day Moving Average : 0.01

Short Percentage : 49.35%

Shares Held by Institutions : 0.00%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.38 (-0.31%)

 USD288.42B 38.66 3.54
CMXHF CSL Limited

+1.98 (+1.00%)

 USD98.64B 42.61 28.39
CSLLY CSL Ltd

+0.81 (+0.81%)

 USD96.65B 41.75 28.39
GNMSF Genmab A/S

+2.40 (+0.53%)

 USD30.42B 36.92 3.71
WXXWY WuXi Biologics (Cayman) Inc

-0.36 (-2.63%)

 USD28.61B 46.76 5.57
WXIBF WuXi Biologics

N/A

 USD28.19B 51.38 5.57
ARGNF argenx SE

N/A

 USD22.32B N/A -22.20
UCBJF UCB SA

N/A

 USD15.22B 16.65 10.95
UCBJY UCB SA ADR

+1.03 (+2.76%)

 USD14.26B 15.57 10.95
SHJBF Shanghai Junshi Biosciences Co..

N/A

 USD13.48B N/A -4.32

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.33% 83% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.33% 82% B- 76% C
Trailing 12 Months  
Capital Gain 19.23% 89% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.23% 89% B+ 84% B
Trailing 5 Years  
Capital Gain -70.48% 50% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.48% 50% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 34.08% 71% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.08% 70% C- 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 237.71% 21% F 19% F
Risk Adjusted Return 14.34% 59% F 45% F
Market Capitalization 2.61M 25% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.62 92% A- 94% A
Price/Book Ratio 0.56 87% B+ 79% C+
Price / Cash Flow Ratio -0.04 25% F 55% F
EV/EBITDA -0.17 28% F 54% F
Management Effectiveness  
Return on Equity 111.59% 100% A+ 99% A+
Return on Invested Capital -456.89% 6% F 3% F
Return on Assets -228.91% 11% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.35 40% F 26% F
Short Percent 49.35% 3% F 6% F
Beta 5.48 2% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.